3-甲基-1-(2-吡啶基)哌嗪盐酸盐 | 63286-11-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 3-甲基-1-(2-吡啶基)哌嗪盐酸盐
• 英文名称: 3-methyl-1-(2-pyridinyl)piperazine
• 英文别名: 3-methyl-1-pyridin-2-yl-piperazine；1-(2-Pyridyl)-3-methylpiperazin；3-methyl-1-pyridin-2-ylpiperazine
• CAS: 63286-11-3
• 化学式: C₁₀H₁₅N₃
• 分子量: 177.249
• InChiKey: JOONLELIXITVDH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  28.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-甲基-1-(2-吡啶基)哌嗪盐酸盐 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 、 甲苯 为溶剂， 生成 N-(4-Amino-phenyl)-3-(2-methyl-4-pyridin-2-yl-piperazin-1-yl)-propionamide
  参考文献：
  名称：

  1-2-(Pyridinyl)piperazine derivatives with antianaphylactic, antibronchospastic and mast cell stabilizing activities

  摘要：

  New 1-(2-pyridinyl)piperazine derivatives were synthesized and tested as inhibitors of the reaginic passive cutaneous anaphylaxis in the rat (PCA), of the histamine-induced bronchospasm in the guinea pig, and of the rat mesenteric mast cell degranulation induced by compound 48/80. On the basis of test results, a series of N-(substituted phenyl)-omega-[4-(2-pyridinyl)-1-piperazinyl]alkanamides was prepared. The nature of substituents at the anilide ring strongly influenced mast cell stabilizing activity, whereas it was less determining in the case of the other two tests. No clear correlation between the most common physicochemical parameters (pi, sigma, Vw volume) of substituents and activity could be detected. With regard to the position of substituents at the anilide ring, the rank order of potency, in the PCA and bronchoconstriction tests, was para greater than meta greater than ortho. Introduction of substituents in the 1-(2-pyridinyl)piperazinyl moiety of the N-(substituted phenyl)propanamide derivatives hardly affected activity, or the effect was deleterious. Some of the new compounds exhibited a simultaneous remarkable activity in all the three assays employed.

  DOI：

  10.1021/jm00384a002
• 作为产物：
  描述：

  2-氯吡啶 、 2-甲基哌嗪 在 2-甲基-2-丁醇 2,2'-联吡啶 、 nickel diacetate 、 sodium hydride 、 苯乙烯 作用下， 以 四氢呋喃 为溶剂， 反应 10.5h， 以54%的产率得到3-甲基-1-(2-吡啶基)哌嗪盐酸盐
  参考文献：
  名称：

  镍催化仲二胺的选择性N-芳基化或N，N'-二芳基化

  摘要：

  描述了使用与2,2'-联吡啶缔合的Ni（0）的催化剂组合，从相应的二胺和芳基氯化物选择性合成N-芳基或N，N'-二芳基哌嗪和三亚甲基（双）哌啶。Ni / 2，2'-联吡啶催化剂对于哌嗪的顺序芳基化也是有效的。报道了新型和不对称的1，4-二芳基哌嗪的制备。

  DOI：

  10.1016/s0040-4020(02)00750-0

文献信息

• Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
  申请人：Gangloff Anthony R.

  公开号：US20100190763A1

  公开（公告）日：2010-07-29

  Disclosed are compounds of the following formula: in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X, and t are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.

  披露了以下公式的化合物： 其中R1、R2、R3、R4、R5、R6、R7、X和t在规范中定义。还披露了含有这些化合物的药物组合物、试剂盒和制造物品，以及用于制备这些化合物的方法和中间体，以及使用这些化合物治疗与PARP活性相关的疾病、紊乱和状况的方法。
• [EN] FUSED PYRROLEDICARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] PYRROLEDICARBOXAMIDES FUSIONNÉS ET LEUR UTILISATION EN TANT QUE PRODUITS PHARMACEUTIQUES
  申请人：SANOFI SA

  公开号：WO2013113860A1

  公开（公告）日：2013-08-08

  The present invention relates to fused pyrroledicarboxamides of the formula (I), in which R1 to R9, X, m and n are as defined in the claims. The compounds of the formula (I) are inhibitors of the acid-sensitive potassium channel TASK-1 and suitable for the treatment of TASK-1 channel-mediated diseases such as arrhythmias, in particular atrial arrhythmias like atrial fibrillation or atrial flutter, and respiratory disorders, in particular sleep-related respiratory disorders like sleep apnea, for example.

  本发明涉及公式（I）中的融合吡咯二羧酰胺，其中R1至R9、X、m和n如权利要求中所定义。公式（I）化合物是酸敏感钾通道TASK-1的抑制剂，适用于治疗TASK-1通道介导的疾病，如心律失常，特别是心房心律失常，如心房颤动或心房扑动，以及呼吸系统疾病，特别是与睡眠相关的呼吸系统疾病，如睡眠呼吸暂停症等。
• Poly (ADP-Ribose) Polymerase (PARP) INHIBITORS
  申请人：Gangloff Anthony R.

  公开号：US20110158989A1

  公开（公告）日：2011-06-30

  Disclosed are compounds of the following formula: in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X, and t are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.

  本发明涉及以下式的化合物：其中R1，R2，R3，R4，R5，R6，R7，X和t在规范中定义。本发明还涉及含有这些化合物的制药组合物、工具箱和制造物品、制备这些化合物有用的中间体和方法，以及使用这些化合物治疗与PARP活性相关的疾病、障碍和病况的方法。
• HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
  申请人：McCall John M.

  公开号：US20120232056A1

  公开（公告）日：2012-09-13

  Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

  本文披露了新的杂环化合物和组合物，并将其应用作药物治疗疾病。还提供了抑制人类或动物主体中PAS激酶（PASK）活性的方法，以治疗糖尿病等疾病。
• POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20130274239A1

  公开（公告）日：2013-10-17

  Disclosed are compounds of the following formula: in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X, and t are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.

  本发明涉及以下式子的化合物：其中R1、R2、R3、R4、R5、R6、R7、X和t在规范中定义。本发明还涉及含有该化合物的药物组合物、试剂盒和制造物品，制备该化合物的有用中间体和方法，以及使用该化合物治疗与PARP活性相关的疾病、疾病和情况的方法。